Pfizer is currently trading at RS. 5134.85, up by 94.05 points or 1.87% from its previous closing of RS. 5040.80 on the BSE.

The stock opened at RS. 5100.00 and touched a high of RS. 5188.00 and a low of RS. 5100.00. A total of 601 shares have been traded so far.

Pfizer, a BSE group 'A' stock with a face value of RS. 10, recorded a 52-week high of RS. 6452.85 on September 2, 2024, and a 52-week low of RS. 3742.90 on April 7, 2025. Over the past week, the scrip’s high and low stood at RS. 5200.00 and RS. 4921.45, respectively. The company’s current market capitalization is RS. 23554.59 crore.

Promoters hold 63.92% of the company’s shares, while institutions and non-institutions hold 19.62% and 16.45%, respectively.

In a significant healthcare development, Pfizer has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. Offering broader serotype coverage, PCV20 protects against 20 clinically relevant serotypes responsible for most invasive and non-invasive pneumococcal diseases.

The vaccine is available as a single shot and may eliminate the need for a second dose. It is particularly crucial for adults over 50 years and individuals with chronic conditions such as asthma, COPD, chronic kidney disease, and diabetes, who are at higher risk of severe pneumococcal infections that can lead to hospitalization or death.

Timely immunization with PCV20 is expected to reduce the risk of severe illness, hospitalization, and mortality, strengthening Pfizer’s 25-year legacy in pneumococcal vaccine innovation and commitment to preventive healthcare in India.

Pfizer operates in manufacturing, marketing, trading, and export of pharmaceutical products.